A protein called STAT3 protected nerve cells from degeneration and improved behavioral and motor outcomes in a rat model of Parkinson’s disease, a study reveals. STAT3 potentially offers “a new avenue for treatment against Parkinson’s,” researchers wrote in the study “STAT3 protects dopaminergic neurons against…
A study reports that the proteins NAP1 and SINTBAD play a role in regulating mitophagy, a process wherein damaged mitochondria are removed from cells, which is essential for helping them stay healthy. Mitophagy is impaired in Parkinson’s disease. “Targeting these proteins in [nerve cells] could be a potential avenue…
A new visual diagnostic technique called Cap-QuIC has the potential to advance the early detection of neurodegenerative diseases, such as Parkinson’s disease. “The simplicity and efficiency of Cap-QuIC could lower the barriers to routine screening for neurodegenerative diseases, ultimately leading to earlier intervention and better patient outcomes,” Hye Yoon…
Depletion of the neurotransmitter dopamine, which occurs in people with Parkinson’s disease, disrupts the balance of motor pathways in the basal ganglia, a group of interconnected structures in the brain that facilitate movement, a study found. “We found that the relative strength of the two motor pathways switches in…
Clumps of RNA-binding proteins have been discovered in the nucleus of nerve cells derived from people with Parkinson’s disease, according to a new study. Generated by a “self-propagating” cycle, these clumps were different and separate from those made from the protein alpha-synuclein, a well-known feature of Parkinson’s. A second…
Six months of once-daily buntanetap halted cognitive decline among people in the early stages of Parkinson’s disease, and improved cognition in those with mild dementia. That’s according to new data from a Phase 3 trial (NCT05357989), which showed that the therapy candidate, developed by Annovis Bio,…
Once-daily treatment with Gain Therapeutics‘ GT-02287 rescued motor function and cognitive performance in a mouse model of Parkinson’s disease associated with mutations in the GBA1 gene. “These data further confirm our conviction that GT-02287 can slow or stop progression of Parkinson’s disease and given the cognitive decline observed…
Six genetic variants associated with mortality and motor progression have been discovered in people with Parkinson’s disease. These newly detected genetic factors that influenced disease progression were largely different from those that increased Parkinson’s risk, researchers found. “This work will help us to better understand the biology of [Parkinson’s]…
Dosing has begun in a Phase 1 clinical trial evaluating the safety and efficacy of IRL757, an oral candidate for apathy treatment in people with Parkinson’s disease and other neurological conditions. Irlab Therapeutics, the therapy’s developer, recently announced the trial’s launch following approval by the Swedish Medical…
The U.S. Senate has joined the House of Representatives in approving The National Plan to End Parkinson’s Act, the first piece of federal legislation dedicated to ending Parkinson’s disease. Celebrated by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the bill now will be sent to…
Get regular updates to your inbox.
